Genmab — August 2015
-
Der er i burde ikke være noget i regnskabet som kan overraske markedet - altså undtagen Børsens journalister.
-
-
Vi har endnu ikke fået kurspåvirkende nyheder, og vi er vel endnu i limbo frem til dara godkendelse
-
Sådan er det bare.
-
Jeg var dog noget overrasket over det voldsomme ryk op mod 690'erne i starten af måneden, og håber på noget nyt til at understøtte videre fremgang
-
....og hvor pokker bliver alle IND'erne af!?
-
Jeg undrer mig sjældent over kursbevægelser i biotek.
-
Er ret rummelig over for den slags.
-
Haha. Jeg undrer mig altid!
-
Firmaer der er højt prissat på forhåbninger vil altid svinge meget i aktiekursen.
-
Derfor er de vel næsten også de mest interessante
-
Specielt når renten er nul
-
Blocked for legal reasons
Sorry, this content is not available in your region.
(finance.thetelegraph.com)
-
Did Gilead Sciences Just Give Wall Street a Huge Head Fake? | The Motley Fool
Gilead Sciences is believed to be seriously interested in acquiring a hematology/oncology company in the near future. But management threw some cold water on this notion in its second-quarter conference call. Are these comments sincere, or did the biotech just throw the Street a curve ball to hide its real intentions?
The Motley Fool (www.fool.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind